DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Information source: Georgetown University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Advanced Solid Tumor Malignancies

Intervention: PD-0332991 (Drug); 5-FU (Drug); Oxaliplatin (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Georgetown University

Official(s) and/or principal investigator(s):
Michael Pishvaian, MD PhD, Principal Investigator, Affiliation: Georgetown University

Overall contact:
Ion Cotarla, Phone: 202-687-4510, Email: ic34@georgetown.edu


This study is for patients with advanced solid tumor malignancies (cancer that has spread to other parts of the body). The purpose of this study is to test the safety and effectiveness of a new combination of drugs, PD-0332991 and 5-Fluorouracil and Oxaliplatin for patients with advanced solid tumor malignancies . PD-0332991 stops cells from dividing by blocking an enzyme called cyclin-dependent kinase (CDK), which cancer cells need to grow and divide. By inhibiting this enzyme, PD-0332991 prevent cancer cells from growing and dividing, while the 5-Fluorouracil and Oxaliplatin damage the cells, hopefully increasing the killing of cancer cells, thus decreasing the tumors in the body. PD-0332991 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in colorectal cancer. It is given as a pill which is taken once a day for one week followed by one week off. 5-Fluorouracil and Oxaliplatin are administered as an infusion into a vein once every 2 weeks and are approved for and used as chemotherapy for several cancers.

Clinical Details

Official title: A Phase I Study of the CDK4/6 Inhibitor PD-0332991, 5-Fluorouracil, and Oxaliplatin in Patients With Advanced Solid Tumor Malignancies

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Recommended Phase 2 dose and schedule

Secondary outcome:



Response rate

Disease control rate

Trough level of PD-0332991 on Day 1 of Cycles 1-4


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Retinoblastoma-positive, histologically proven advanced solid tumor malignancies for

which no curative therapy exists

- Biopsy accessible tumor deposits

- Corrected QT interval less than 500 milliseconds by EKG

- ECOG preformance status 0-2

- Subjects with no brain metastases or a history of previously treated brain metastases

who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment.

- Adequate hepatic, bone marrow, and renal function

- Partial thromboplastin time must be Subjects on anticoagulant will be permitted to enroll as long as the INR is in acceptable therapeutic range.

- Life expectancy > 12 weeks

- Women of childbearing potential must have a negative serum pregnancy test within 14

days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months.

- Subject is capable of understanding and complying with parameters of the protocol and

able to sign and date the informed consent. Exclusion Criteria:

- Intolerant of, or ineligible for 5-FU, oxaliplatin and/or the combination of both

- CNS metastases that do not meet the criteria outlined in the inclusion criteria

- Peripheral neuropathy >/= Grade 2 at baseline or peripheral neuropathy >/= Grade 1

with neuropathic pain

- Active severe infection or known chronic infection with HIV or hepatitis B virus

- Cardiovascular disease problems including unstable angina, therapy for

life-threatening ventricular arrhythmia or myocardial infarction, stroke, or congestive heart failure within the last 6 months.

- Life-threatening visceral disease or other severe concurrent disease

- Women who are pregnant or breastfeeding

- Anticipated patient survival under 3 months

- Concurrent use of known CYP 3A4 inhibiting or activating medications

- Clinically significant and uncontrolled major medical condition(s)

Locations and Contacts

Ion Cotarla, Phone: 202-687-4510, Email: ic34@georgetown.edu

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia 20007, United States; Recruiting
Ion Cotarla, Phone: 202-687-4510, Email: ic34@georgetown.edu
Christine Fasano, RN, Phone: 202-687-2007, Email: cff42@georgetown.edu
Michael Pishvaian, MD PhD, Principal Investigator
Additional Information

Starting date: December 2011
Last updated: February 13, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017